💊 İlaçlar A-Z 🧬 Hedefler 🛠 Araçlar 📚 Rehberler
Tüm İlaçlar İlaç Sınıfları Terapötik Alanlar Yan Etkiler
Rehberler Sözlük Zaman Çizelgesi
Karşılaştırmalar İlaç Yolculukları İlaç Aileleri
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sitagliptin Phosphate

CHEMBL1201174 Phase 4 Onaylandı Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
523.3 g/mol
LogP
—
Phase
4

A phosphate salt form of sitagliptin with the same therapeutic properties. This once-daily pill helps control blood sugar in type 2 diabetes by preventing the breakdown of incretin hormones that naturally stimulate insulin release after eating.

Moleküler Ağırlık

523,3200 g/mol

TPSA

156,00 Ų

Terapötik Alanlar

Benign Prostatic Hyperplasia Cardiovascular Disease Rheumatoid Arthritis Osteoporosis Psoriasis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Hyperlipidemia Obesity Lymphoma Type 2 Diabetes Hypertension Hepatitis C Heart Failure Colorectal Cancer Leukemia

Etki Mekanizması

DPP-4 inhibitor increasing incretin levels.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

DPP-4 inhibitor increasing incretin levels.

2D Yapı

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O.O=P(O)(O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C16H15F6N5O.H3O4P.H2O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;1-5(2,3)4;/h4,6,9H,1-3,5,7,23H2;(H3,1,2,3,4);1H2/t9-;;/m1../s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C16H20F6N5O6P

                    

                    
                    

                        
HBD / HBA

                        
5 / 15

                    

                    
                    

                        
Döndürülebilir Bağlar

                        
4

                    

                    
                    
                    

                        
Ağır Atomlar

                        
34

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Sıkça Sorulan Sorular

                

                    
                    

                        
                        

                            
A phosphate salt form of sitagliptin with the same therapeutic properties. This once-daily pill helps control blood sugar in type 2 diabetes by preventing the breakdown of incretin hormones that naturally stimulate insulin release after eating.

                        

                    

                    

                    

                    
                    

                        
                        

                            
DPP-4 inhibitor increasing incretin levels.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Sitagliptin Phosphate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201174.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 11591741.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Tıbbi Sorumluluk Reddi

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.